Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colorectal cancer||not applicable||ETBX-011||Phase Ib/II||Actionable||In a Phase I/II trial, ETBX-011 treatment resulted in an overall survival of 11 months, and survival at 12 months follow-up in 48% of patients with metastatic colorectal cancer (Journal of Clinical Oncology 32, no. 15_suppl (May 2014) 3093-3093; NCT01147965.).||detail...|
|PubMed Id||Reference Title||Details|
|Immunotherapeutic treatment of metastatic colorectal cancer using ETBX-011.||Full reference...|